Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1/M2 translation

British Journal of Clinical Pharmacology

Volumn 84, Issue 1, 2018, Pages 25-34

  Beigel, John H ^a   Voell, Jocelyn ^b   Muñoz, Paula ^b   Kumar, Parag ^c   Brooks, Kristina M ^c   Zhang, Jianbo ^d   Iversen, Patrick ^d,e   Heald, Alison ^d,f   Wong, Michael ^d,g   Davey, Richard T ^b  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d AVI BIOPHARMA INC   (United States)

^e OREGON STATE UNIVERSITY   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

antiviral; phosphorodiamidate morpholino oligomer; therapeutic

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; RADAVIRSEN; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; M1 PROTEIN, INFLUENZA A VIRUS; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; MORPHOLINO OLIGONUCLEOTIDE; PLACEBO;

ADULT; ALBUMINURIA; ANTISENSE THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CHILL; COMMON COLD; CONTROLLED STUDY; COUGHING; CREATININE URINE LEVEL; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; ELIMINATION HALF-LIFE; FATIGUE; FEMALE; FOLLOW UP; GINGIVITIS; HEADACHE; HEART PALPITATION; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; INCREASED APPETITE; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; SYSTOLIC HYPERTENSION; CHEMICALLY INDUCED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; GENETICS; INCIDENCE; INFLUENZA; INFLUENZA A VIRUS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROTEIN SYNTHESIS; VIROLOGY; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEADACHE; HEALTHY VOLUNTEERS; HUMANS; INCIDENCE; INFLUENZA A VIRUS; INFLUENZA, HUMAN; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MORPHOLINOS; OLIGONUCLEOTIDES, ANTISENSE; PLACEBOS; PROTEIN BIOSYNTHESIS; PROTEINURIA; VIRAL MATRIX PROTEINS; YOUNG ADULT;

EID: 85038437411     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13405     Document Type: Article

References (11)

1. Kabanov AV, Vinogradov SV, Ovcharenko AV, Krivonos AV, Melik-Nubarov NS, Kiselev VI, et al. A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells. FEBS Lett 1990; 259: 327–330.
2. Zamecnik PC, Agrawal S. Oligodeoxynucleotide hybridization inhibition of HIV and influenza virus. Nucleic Acids Symp Ser 1991; 127–131.
3. Mizuta T, Fujiwara M, Abe T, Miyano-Kurosaki N, Yokota T, Shigeta S, et al. Inhibitory effects of an antisense oligonucleotide in an experimentally infected mouse model of influenza a virus. Biochem Biophys Res Commun 2000; 279: 158–161.
4. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A 2004; 101: 8676–8681.
5. Gabriel G, Nordmann A, Stein DA, Iversen PL, Klenk HD. Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza a H7N7 virus. J Gen Virol 2008; 89: 939–948.
6. Lupfer C, Stein DA, Mourich DV, Tepper SE, Iversen PL, Pastey M. Inhibition of influenza a H3N8 virus infections in mice by morpholino oligomers. Arch Virol 2008; 153: 929–937.
7. Engelhardt JA. Comparative renal Toxicopathology of antisense oligonucleotides. Nucleic Acid Ther 2016; 26: 199–209.
8. Crooke ST, Baker BF, Kwoh TJ, Cheng W, Schulz DJ, Xia S, et al. Integrated safety assessment of 2′-O-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. Mol Ther 2016; 24: 1771–1782.
9. Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Telethon Foundation DMDIN. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 2016; 79: 257–271.
10. Heald AE, Charleston JS, Iversen PL, Warren TK, Saoud JB, Al-Ibrahim M, et al. AVI-7288 for Marburg virus in nonhuman primates and humans. N Engl J Med 2015; 373: 339–348.
11. Heald AE, Iversen PL, Saoud JB, Sazani P, Charleston JS, Axtelle T, et al. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies. Antimicrob Agents Chemother 2014; 58: 6639–6647.